Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: New imaging strategies to guide molecular therapies

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 2, 2010, Pages 386-398

  Malviya, G ^a   Conti, F ^b   Chianelli, M ^a,c   Scopinaro, F ^d   Dierckx, R A ^a   Signore, A ^a,d  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biological therapies; Molecular imaging; Monoclonal antibodies; Rheumatoid arthritis; Therapy decision making

Indexed keywords

ADALIMUMAB; CD20 ANTIBODY; CD3 ANTIBODY; CD4 ANTIBODY; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 6; INTERLEUKIN 8; OKT 3; RITUXIMAB; TECHNETIUM 99M; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; FOLLOW UP; HUMAN; IMMUNOMODULATION; ISOTOPE LABELING; MEDICAL DECISION MAKING; MOLECULAR IMAGING; PATIENT SELECTION; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SCINTIGRAPHY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; HUMANS; ISOTOPE LABELING; MOLECULAR PROBE TECHNIQUES; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOIMMUNODETECTION; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 77949272766     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1272-0     Document Type: Review

References (86)

1. MF Doran CS Crowson GR Pond WM O'Fallon SE Gabriel 2002 Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study Arthritis Rheum 46 2287 2293 10.1002/art.10524 12355475
2. E Baecklund A Ekbom P Sparén N Feltelius L Klareskog 1998 Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study BMJ 317 180 181 1:STN:280:DyaK1czjt1KltA%3D%3D 9665898
3. DH Solomon EW Karlson EB Rimm CC Cannuscio LA Mandl JE Manson, et al. 2003 Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis Circulation 107 1303 1307 10.1161/01.CIR.0000054612.26458.B2 12628952 (Pubitemid 36314415)
4. F Wolfe B Freundlich WL Straus 2003 Increase in cardiovascular disease prevalence in rheumatoid arthritis J Rheumatol 30 36 40 12508387
5. E Thomas DH Brewster RJ Black GJ Macfarlane 2000 Risk of malignancy among patients with rheumatic conditions Int J Cancer 88 497 502 10.1002/1097- 0215(20001101)88:3<497::AID-IJC27>3.0.CO;2-J 1:STN:280: DC%2BD3crgsl2guw%3D%3D 11054684 (Pubitemid 30747077)
6. F Wolfe DM Mitchell JT Sibley JF Fries DA Bloch CA Williams, et al. 1994 The mortality of rheumatoid arthritis Arthritis Rheum 37 481 494 10.1002/art.1780370408 1:STN:280:DyaK2c7pslOrsw%3D%3D 8147925
7. RB Landewé M Boers AC Verhoeven R Westhovens MA van de Laar HM Markusse, et al. 2002 COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention Arthritis Rheum 46 2 347 356 10.1002/art.10083 11840436 (Pubitemid 34136571)
8. SE Gabriel CS Crowson HM Kremers MF Doran C Turesson WM O'Fallon, et al. 2003 Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years Arthritis Rheum 48 54 58 10.1002/art.10705 12528103 (Pubitemid 36091647)
9. JR O'Dell CE Haire N Erikson W Drymalski W Palmer PJ Eckhoff, et al. 1996 Treatment of rheumatoid arthritis with methotrexate, sulphasalazine and hydroxychloroquine, or a combination of these medications New Engl J Med 334 1287 1291 10.1056/NEJM199605163342002 8609945 (Pubitemid 26138009)
10. RB Landewè M Boers AC Verhoeven R Westhovens MA van de Laar HM Markusse, et al. 2002 COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention Arthritis Rheum 46 2 347 356 10.1002/art.10083 11840436 (Pubitemid 34136571)
11. EH Choy GH Kingsley GS Panayi 1998 Monoclonal antibody therapy in rheumatoid arthritis Br J Rheumatol 37 484 490 10.1093/rheumatology/37.5.484 1:STN:280:DyaK1czhtlSqsQ%3D%3D 9651073
12. PT Fan KH Leong 2007 The use of biological agents in the treatment of rheumatoid arthritis Ann Acad Med Singapore 36 128 134 17364080
13. M Chianelli C D'Alessandria F Conti R Priori G Valesini A Annovazzi, et al. 2006 New radiopharmaceuticals for imaging rheumatoid arthritis Q J Nucl Med Mol Imaging 50 217 225 1:STN:280:DC%2BD28vksFGitg%3D%3D 16868535
14. G Kohler C Milstein 1975 Continuous cultures of fused cells secreting antibody of predefined specificity Nature 256 495 497 10.1038/256495a0 1:STN:280:DyaE28%2FhtVOhtQ%3D%3D 1172191
15. OH Brekke I Sandlie 2003 Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat Rev Drug Discov 2 52 62 10.1038/nrd984 1:CAS:528:DC%2BD3sXntF0%3D 12509759 (Pubitemid 37361624)
16. I Aksentijevich IW Flinn 2002 Monoclonal antibody therapy with autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma Cancer Control 9 2 99 105 12008655
17. SL Morrison MJ Johnson LA Herzenberg VT Oi 1984 Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains Proc Nat Acad Sci 81 6851 6855 10.1073/pnas.81.21.6851 1:CAS:528: DyaL2MXit1Ggtg%3D%3D 6436822 (Pubitemid 15221019)
18. SB Hanauer 1999 Safety of infliximab in clinical trials Aliment Pharmacol Ther 13 16 22 10.1046/j.1365-2036.1999.00027.x 1:CAS:528:DyaK1MXmsl2iu7k%3D 10597335
19. OH Brekke I Sandlie 2003 Therapeutic antibodies for human diseases at the dawn of the twenty-first century Nat Rev Drug Discov 2 52 62 10.1038/nrd984 1:CAS:528:DC%2BD3sXntF0%3D 12509759 (Pubitemid 37361624)
20. PT Jones PH Dear J Foote MS Neuberger G Winter 1986 Replacing the complementarity-determining regions in a human antibody with those from a mouse Nature 321 522 525 10.1038/321522a0 1:CAS:528:DyaL28Xkt1aksbY%3D 3713831
21. MA Holmes TN Buss J Foote 1998 Conformational correction mechanisms aiding antigen recognition by a humanized antibody J Exp Med 187 479 485 10.1084/jem.187.4.479 1:CAS:528:DyaK1cXhtFCqt78%3D 9463398 (Pubitemid 28093350)
22. S Mascheretti S Schreiber 2004 The role of pharmacogenomics in the prediction of efficacy of anti-TNF therapy in patients with Crohn's disease Pharmacogenomics 5 5 479 486 10.1517/14622416.5.5.479 1:CAS:528: DC%2BD2cXltVKls7o%3D 15212584 (Pubitemid 39023064)
23. HR Hoogenboom 2005 Selecting and screening recombinant antibody libraries Nat Biotechnol 23 1105 1116 10.1038/nbt1126 1:CAS:528:DC%2BD2MXpvVyrsb0%3D 16151404 (Pubitemid 41486392)
24. N Lonberg 2005 Human antibodies from transgenic animals Nat Biotechnol 23 1117 1125 10.1038/nbt1135 1:CAS:528:DC%2BD2MXpvVyrtrw%3D 16151405 (Pubitemid 41486393)
25. M Trikha L Yan MT Nakada 2002 Monoclonal antibodies as therapeutics in oncology Curr Opin Biotechnol 13 609 614 10.1016/S0958-1669(02)00348-8 1:CAS:528:DC%2BD38XptlWlsbg%3D 12482522 (Pubitemid 35448064)
26. AN Weir A Nesbitt AP Chapman AG Popplewell P Antoniw AD Lawson 2002 Formatting antibody fragments to mediate specific therapeutic functions Biochem Soc Trans 30 512 516 10.1042/BST0300512 1:CAS:528:DC%2BD38XntVentrs%3D 12196125 (Pubitemid 35001587)
27. VV Kaushik RJ Moots 2005 CDP-870 (Certolizumab) in rheumatoid arthritis Expert Opin Biol Ther 5 4 601 606 10.1517/14712598.5.4.601 1:CAS:528: DC%2BD2MXjt1ynu7k%3D 15934837 (Pubitemid 40593341)
28. DM Knight H Trinh J Le S Siegel D Shealy M McDonough, et al. 1993 Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 30 1443 1453 10.1016/0161-5890(93)90106-L 1:CAS:528:DyaK2cXivFSisw%3D%3D 8232330
29. BJ Scallon MA Moore H Trinh DM Knight J Ghrayeb 1995 Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions Cytokine 7 251 259 10.1006/cyto.1995.0029 1:CAS:528:DyaK2MXls1ait70%3D 7640345
30. DL Scott GH Kingsley 2006 Tumor necrosis factor inhibitors for rheumatoid arthritis N Eng J Med 355 704 712 10.1056/NEJMct055183 1:CAS:528: DC%2BD28Xot12ltro%3D (Pubitemid 44244541)
31. T ten Hove C van Montfrans MP Peppelenbosch SJ van Deventer 2002 Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease Gut 50 206 211 10.1136/gut.50.2.206 11788561
32. SA Siegel DJ Shealy MT Nakada J Le DS Woulfe L Probert, et al. 1995 The mouse/human chimeric monoclonal antibody cA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo Cytokine 7 15 25 10.1006/cyto.1995.1003 1:CAS:528:DyaK2MXjs1ehtL0%3D 7538333
33. D Barone C Krantz D Lambert K Maggiora K Mohler 1999 Comparative analysis of the ability of Etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion Arthritis Rheum 42 Suppl S90
34. A Annovazzi C D'Alessandria R Caprilli A Viscido F Corsetti MG Parisella, et al. 2002 Radiolabelling of a monoclonal anti-TNF-α antibody with 99mTc: in vitro studies Q J Nucl Med Mol Imaging 46 Suppl 1 27
35. 99mTc-infliximab Arthritis Rheum 52 4 1224 1226 10.1002/art.20979 15818709 (Pubitemid 40530130)
36. PJ Anderson 2005 Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles Semin Arthritis Rheum 34 Suppl 19 22 10.1016/j.semarthrit.2005.01.005 1:CAS:528:DC%2BD2MXjtVyrtLk%3D 15852250
37. R Rau 2002 Adalimumab (a fully human anti-tumour necrosis factor a monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials Ann Rheum Dis 61 Suppl II 70 73
38. Adalimumab (Humira). European Public Assessment Report - Scientific Discussion. http://www.emea.europa.eu/humandocs/PDFs/EPAR/humira/Humira-H-481- II-43-AR.pdf (assessed on 01.07.08).
39. MJ Abrams M Juweid CI tenKate DA Schwartz MM Hauser FE Gaul, et al. 1990 Technetium-99m-human polyclonal IgG radiolabelled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats J Nucl Med 31 2022 2028 1:CAS:528:DyaK3MXhvVWns70%3D 2266401
40. P Barrera WJ Oyen OC Boerman PL van Riel 2003 Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis Ann Rheum Dis 62 825 828 10.1136/ard.62.9.825 1:CAS:528:DC%2BD3sXns1SisLY%3D 12922953 (Pubitemid 37026491)
41. 99mTechnetium labelled anti-TNF-α antibodies for the therapy decision-making and follow-up of patients with rheumatoid arthritis Q J Nucl Med Mol Imaging 52 Suppl 1(2) 13 14
42. Rituxan® (Rituximab), package insert. Genentech Inc., San Francisco, CA; revised September, 2008. http://www.gene.com/gene/products/information/pdf/ rituxan-prescribing.pdf (assessed on 02/10/08).
43. P Stashenko LM Nadler R Hardy SF Schlossman 1980 Characterization of a human B lymphocyte-specific antigen J Immunol 125 1678 1685 1:STN:280: DyaL3M%2Fgsl2rtg%3D%3D 6157744
44. TF Tedder AW Boyd AS Freedman LM Nadler SF Schlossman 1985 The B cell surface molecule B1 is functionally linked with B-cell activation and differentiation J Immunol 135 2 973 979 1:CAS:528:DyaL2MXltVejtrs%3D 3925015
45. T Dorner 2003 Rumester, G. The role of B-cells in rheumatoid arthritis: mechanisms and therapeutic targets Curr Opin Rheumatol 15 246 252 10.1097/00002281-200305000-00011 12707577 (Pubitemid 36532604)
46. ME Reff K Carner KS Chambers PC Chinn JE Leonard R Raab, et al. 1994 Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 435 445 1:CAS:528:DyaK2cXhtVCnu70%3D 7506951
47. PW Johnson MJ Glennie 2001 Rituximab: mechanisms and applications Br J Cancer 85 1619 1623 10.1054/bjoc.2001.2127 1:CAS:528:DC%2BD38XnsVCitA%3D%3D 11742477 (Pubitemid 34081502)
48. AJ Olszewski ML Grossbard 2004 Empowering targeted therapy: lessons from Rituximab Sci STKE 2004 241 30 10.1126/stke.2412004pe30
49. 99mTc-rituximab radiolabelled by photo-activation: a new non-Hodgkin's lymphoma imaging agent Eur J Nucl Med 33 53 59 10.1007/s00259-005-1838-4 (Pubitemid 41785309)
50. MA Stalteri SJ Mather 1996 Technetium-99m labelling of the antitumour antibody PR1A3 by photoactivation Eur J Nucl Med 23 178 187 10.1007/BF01731842 1:CAS:528:DyaK28XitV2ht78%3D 8925853 (Pubitemid 26056996)
51. 99mTc-Rituximab for breast patient Zhonghua Zhong Liu Za Zhi (Chinese J Oncol) 28 3 200 203 1:CAS:528:DC%2BD2sXnvVejt70%3D
52. G Malviya B Laganà F Milanetti C Del Mastro D Familiari RA Dierckx F Scopinaro R D'Amelio A Signore 2008 Use of 99m-technetium labelled Rituximab for imaging of patients with chronic inflammatory diseases Eur J Nucl Med Mol Imaging 35 Suppl 2 S142
53. D Pohlers CB Schmidt-Weber A Franch J Kuhlmann R Bräuer F Emmrich, et al. 2002 Differential clinical efficacy of anti-CD4 monoclonal antibodies in rat adjuvant arthritis is paralleled by differential influence on NF-kB binding activity and TNF-α secretion of T cells Arthritis Res 4 184 189 10.1186/ar404 1:CAS:528:DC%2BD38XjsVCkurw%3D 12010568 (Pubitemid 34460757)
54. MP Reddy CAS Kinney MA Chaikin A Payne J Fishman-Lobell P Tsui, et al. 2000 Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4 J Immunol 164 1925 1933 1:CAS:528: DC%2BD3cXhtlymtLY%3D 10657642
55. U Mason J Aldrich F Breedveld CB Davis M Elliott M Jackson, et al. 2002 CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis J Rheumatol 29 220 229 1:CAS:528:DC%2BD38XhsF2iurg%3D 11838838
56. JD Isaacs MG Wing JD Greenwood BL Hazleman G Hale H Waldmann 1996 A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans Clin Exp Immunol 106 427 433 10.1046/j.1365-2249.1996.d01-876.x 1:STN:280:DyaK2s7ivFSlug%3D%3D 8973608
57. RW Kinne W Becker J Schwab G Horneff A Schwarz JR Kalden, et al. 1993 Comparison of 99Tcm-labelled specific murine anti-CD4 monoclonal antibodies and nonspecific human immunoglobulin for imaging inflamed joints in rheumatoid arthritis Nucl Med Commun 14 8 667 675 10.1097/00006231-199308000-00007 1:STN:280:DyaK3szot1KrsQ%3D%3D 8371892
58. - and non-specific monoclonal antibodies Eur J Nucl Med 21 176 180 10.1007/BF00175768 1:STN:280:DyaK2c3hsFKitA%3D%3D 8162942
59. W Becker F Emmrich G Horneff G Burmester F Seiler A Schwarz, et al. 1990 Imaging rheumatoid arthritis specifically with technetium 99m CD4-specific (T-helper lymphocytes) antibodies Eur J Nucl Med 17 3-4 156 159 10.1007/BF00811445 1:STN:280:DyaK3M7it1WisQ%3D%3D 2149102
60. MP Bevilacqua 1993 Endothelial-leukocytes adhesion molecules Ann Rev Immunol 11 767 804 10.1146/annurev.iy.11.040193.004003 1:CAS:528: DyaK3sXkt1Kjtrw%3D
61. JC Mason DO Haskard 1994 The clinical importance of leucocytes and endothelial cell adhesion molecules in inflammation Vasc Med Rev 5 249 275
62. MP Bevilacqua S Stengelin MA Gimbrone Jr B Seed 1989 Endothelial leucocyte adhesion molecule-1: an inducible receptor for neutrophils related to complement proteins and lectins Science 243 1160 1165 10.1126/science.2466335 1:CAS:528:DyaL1MXmtFeitb0%3D 2466335
63. M Bhushan TO Bleiker AE Ballsdon MH Allen M Sopwith MK Robinson, et al. 2002 Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial Br J Dermatol 146 824 831 10.1046/j.1365-2133.2002.04743.x 1:CAS:528:DC%2BD38Xlt1yqsLk%3D 12000379 (Pubitemid 34539192)
64. JS Pober MP Bevilacqua DL Mendrik LA Lapierre W Fiers MA Gimborn Jr 1986 Two distinct monokines, interleukin 1 and tumor necrosis factor, each in dependently induce biosynthesis and transient expression of the antigen on the surface of cultured human vascular endothelial cells J Immunol 136 1680 1687 1:CAS:528:DyaL28XhsVKrur4%3D 3485132
65. SM Wellicome MH Thornhill C Pitzalis DS Thomas JS Lanchbury GS Panayi, et al. 1990 A monoclonal antibody that detects a novel antigen on endothelial cells that is induced by tumor necrosis factor, IL-1 or lipopolysaccharide J Immunol 144 2558 2565 1:CAS:528:DyaK3cXitlelsLc%3D 2108206
66. MP Bevilacqua RM Nelson 1993 Selectins J Clin Invest 91 379 387 10.1172/JCI116210 1:CAS:528:DyaK3sXitVOlsb8%3D 7679406
67. F Jamar PT Chapman AA Harrison RM Binns DO Haskard AM Peters 1995 Inflammatory arthritis: imaging of endothelial cell activation with an indium-111-labelled F(ab')2 fragment of anti-E-selectin monoclonal antibody Radiology 194 843 850 1:STN:280:DyaK2M7mslWgtQ%3D%3D 7532314
68. PT Chapman F Jamar ET Keelan AM Peters DO Haskard 1996 Use of monoclonal antibody against E-selectin for imaging endothelial activation in rheumatoid arthritis Arthritis Rheum 39 1371 1375 10.1002/art.1780390815 1:STN:280:DyaK28zitVansg%3D%3D 8702446
69. m-labelled human non-specific immunoglobulin in radionuclide imaging of rheumatoid arthritis Brit J Radiol 70 473 481 1:STN:280:DyaK2szntFSjsQ%3D%3D 9227228
70. PA van der Lubbe JW Arndt W Calame TC Ferreira EK Pauwels FC Breedveld 1991 Measurement of synovial inflammation in rheumatoid arthritis with technetium-99m labelled human polyclonal immunoglobulin G Eur J Nucl Med 18 119 123 10.1007/BF00950757 2044570
71. 99mTc-human immunoglobulin scintigraphy- a reliable method to detect joint activity in rheumatoid arthritis J Rheumatol 19 1371 1376 1433003
72. M Liberatore M Clemente AP Iurilli L Zorzin M Marini E Di Rocco, et al. 1992 Scintigraphic evaluation of disease activity in rheumatoid arthritis: a comparison of technetium-99m human non-specific immunoglobulins, leucocytes and albumin nanocolloids Eur J Nucl Med 19 853 857 10.1007/BF00168160 1:STN:280:DyaK3s%2FotlGjsg%3D%3D 1451700
73. F Jamar FA Houssiau J-P Devogelaer PT Chapman DO Haskard V Beaujean, et al. 2002 Scintigraphy using a technetium 99m-labelled anti-E-selectin Fab fragment in rheumatoid arthritis Rhematol 41 53 61 10.1093/rheumatology/41.1.53 1:CAS:528:DC%2BD38Xhtlyks7k%3D
74. ETM Keelan AA Harrison PT Chapman RM Binns AM Peters DO Haskard 1994 Imaging vascular endothelial activation: an approach using radiolabelled monoclonal antibodies against the endothelial cell adhesion molecule E-selectin J Nucl Med 35 276 281 1:CAS:528:DyaK2cXktVCju7Y%3D 7507524
75. TO Utset JA Auger D Peace RA Zivin D Xu L Jolliffe, et al. 2002 Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial J Rheumatol 29 1907 1913 1:CAS:528:DC%2BD38Xns1aksLs%3D 12233885
76. ML Alegre LJ Peterson D Xu HA Sattar DR Jeyarajah K Kowalkowski, et al. 1994 A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo Transplantation 57 1537 1543 1:CAS:528:DyaK2cXlslOht7c%3D 8009586
77. ES Woodle D Xu RA Zivin J Auger J Charette R O'Laughlin, et al. 1999 Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection Transplantation 68 608 616 10.1097/00007890-199909150-00003 1:CAS:528: DyaK1MXms12gu74%3D 10507477 (Pubitemid 29453435)
78. MS Cole KW Stellrecht JD Shi M Homola DH Hsu C Anasetti, et al. 1999 HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro Transplantation 68 4 563 571 10.1097/00007890-199908270-00020 1:CAS:528:DyaK1MXmtF2qtbg%3D 10480417 (Pubitemid 29416634)
79. EG Routledge ME Falconer H Pope IS Lloyd H Waldmann 1995 The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody Transplantation 60 8 847 853 10.1097/00007890-199510270-00015 1:CAS:528:DyaK28XktFSj 7482746
80. M Cole C Anasetti JY Tso 1997 Human IgG2 variants of chimeric anti-CD3 are non-mitogenic to T cells J Immunol 159 3613 3621 1:CAS:528: DyaK2sXmtlOktrg%3D 9317161
81. V Trajkovic 2002 Nuvion Protein Design Labs Curr Opin Investig Drugs 3 3 411 414 1:CAS:528:DC%2BD38XlvVSjsb0%3D 12054088
82. T Dingermann I Zündorf 2006 Macromolecular immunosuppressants Biotechnol J 1 47 57 10.1002/biot.200500003 1:CAS:528:DC%2BD28Xis1Kis7w%3D 16892224
83. C Marcus ML Thakur TV Huynh JS Louie M Leibling C Minami, et al. 1994 Imaging rheumatic joint diseases with anti-T lymphocyte antibody OKT-3 Nucl Med Commun 15 10 824 830 10.1097/00006231-199410000-00008 1:STN:280: DyaK2M7ktVegsg%3D%3D 7838446
84. 99mTc-anti- CD3 Brit J Radiol 81 25 29 10.1259/bjr/63780400 1:STN:280:DC%2BD2sjktlWksA%3D%3D 18039720 (Pubitemid 351154771)
85. G Malviya EFJ De Vries RA Dierckx A Signore 2007 Radiopharmaceuticals for imaging chronic lymphocytic inflammation Bra Arch Bio Tech 50 1 13
86. G Malviya C D'Alessandria C Trotta R Massari A Soluri F Scopinaro, et al. 2008 Radiolabeled-Visilizumab, a humanized anti-CD3 monoclonal antibody, for in vivo targeting of human CD3+ lymphocytes Eur J Nucl Med Mol Imaging 35 Suppl 2 S142